Benzodiazepine withdrawal syndrome: a literature review and evaluation - PubMed (original) (raw)
Review
Benzodiazepine withdrawal syndrome: a literature review and evaluation
G L MacKinnon et al. Am J Drug Alcohol Abuse. 1982.
Abstract
The capacity of the benzodiazepine drugs to produce dependence and addiction has been associated with what has recently been recognized as a benzodiazepine withdrawal syndrome. Abrupt discontinuation of benzodiazepine treatment may show a spectrum of symptoms similar to those observed from withdrawal of alcohol or barbiturates. Such reactions have been reported with and are reviewed for the following drugs: chlordiazepoxide, diazepam, oxazepam, lorazepam, nitrazepam, temazepam, and clobazam. Generally, the higher the dose and the longer the benzodiazepine is taken, the greater the risk of developing withdrawal symptoms. However, withdrawal symptoms may occur in patients receiving recommended doses and/or short-term therapy. Although most withdrawal reactions have been reported with the long-acting benzodiazepines having psychoactive metabolites, reactions may also occur with the short-acting agents. In contrast, rebound insomnia occurs with greater frequency and severity with the short-acting agents. Benzodiazepine therapy should be stopped as early as possible, with tapering after moderate dose and/or prolonged use therapy.
Similar articles
- Benzodiazepine withdrawal.
Lapierre YD. Lapierre YD. Can J Psychiatry. 1981 Mar;26(2):93-5. doi: 10.1177/070674378102600203. Can J Psychiatry. 1981. PMID: 6114793 - [The withdrawal syndrome in benzodiazepine dependence and its management].
Străulea AO, Chiriţă V. Străulea AO, et al. Rev Med Chir Soc Med Nat Iasi. 2009 Jul-Sep;113(3):879-84. Rev Med Chir Soc Med Nat Iasi. 2009. PMID: 20191849 Romanian. - Benzodiazepine withdrawal effects.
Pecknold JC, McClure DJ, Fleuri D, Chang H. Pecknold JC, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(4-6):517-22. doi: 10.1016/s0278-5846(82)80142-5. Prog Neuropsychopharmacol Biol Psychiatry. 1982. PMID: 6131488 Clinical Trial. - Rebound insomnia: a critical review.
Gillin JC, Spinweber CL, Johnson LC. Gillin JC, et al. J Clin Psychopharmacol. 1989 Jun;9(3):161-72. J Clin Psychopharmacol. 1989. PMID: 2567741 Review. - Withdrawing benzodiazepines in primary care.
Lader M, Tylee A, Donoghue J. Lader M, et al. CNS Drugs. 2009;23(1):19-34. doi: 10.2165/0023210-200923010-00002. CNS Drugs. 2009. PMID: 19062773 Review.
Cited by
- Alprazolam exposure during adolescence induces long-lasting dysregulation in reward sensitivity to morphine and second messenger signaling in the VTA-NAc pathway.
Cardona-Acosta AM, Sial OK, Parise LF, Gnecco T, Enriquez Marti G, Bolaños-Guzmán CA. Cardona-Acosta AM, et al. Sci Rep. 2023 Jul 5;13(1):10872. doi: 10.1038/s41598-023-37696-8. Sci Rep. 2023. PMID: 37407659 Free PMC article. - Enduring neurological sequelae of benzodiazepine use: an Internet survey.
Huff C, Finlayson AJR, Foster DE, Martin PR. Huff C, et al. Ther Adv Psychopharmacol. 2023 Feb 6;13:20451253221145561. doi: 10.1177/20451253221145561. eCollection 2023. Ther Adv Psychopharmacol. 2023. PMID: 36760692 Free PMC article. - Recurrent clonazepam withdrawal delirium in a postoperative neurosurgical patient: a case report.
Lutz EW, Hines C. Lutz EW, et al. BMJ Case Rep. 2021 Jun 23;14(6):e240804. doi: 10.1136/bcr-2020-240804. BMJ Case Rep. 2021. PMID: 34162601 Free PMC article. - A Retrospective Review of Morbidity and Mortality Associated with Acute Benzodiazepine Withdrawal at a Midwestern Academic Medical Center.
Thornton SL, Whitacre J, Pallo N, Roberts N, Oller L. Thornton SL, et al. Kans J Med. 2021 Mar 19;14:77-79. doi: 10.17161/kjm.vol1414653. eCollection 2021. Kans J Med. 2021. PMID: 33763183 Free PMC article. - Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development.
Lerner A, Klein M. Lerner A, et al. Brain Commun. 2019 Oct 16;1(1):fcz025. doi: 10.1093/braincomms/fcz025. eCollection 2019. Brain Commun. 2019. PMID: 32954266 Free PMC article. Review.